Liquidia Corporation (LQDA) stock analysis
LQDA · Liquidia Corporation
Latest recorded price: USD 56.37
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
Fiscal 2025 figures: revenue growth 115.0%, free cash flow margin -25.3%. The model flags 2 risk signals for this company (1 high severity).
Similar companies in Healthcare
- Neurocrine Biosciences, Inc. - Common Stock (NBIX)
- Phibro Animal Health Corporation (PAHC)
- Prestige Consumer Healthcare Inc. (PBH)
- Pacira BioSciences, Inc. (PCRX)
- Perrigo Company plc (PRGO)
- Supernus, Inc. - Common Stock (SUPN)
- Teva Pharmaceutical Industries Limited Ordinary Shares (TEVA)
- Trulieve Cannabis Corp. (TRLV)